Halberd Corporation CEO Answers Shareholders' Questions Regarding Covid-19 Treatment
Halberd Corp. (OTC PINK: HALB) provides insights into its patented extracorporeal treatment for COVID-19 in a recent response from CEO William A. Hartman. The unique process aims to remove disease antigens from bodily fluids through a method akin to kidney dialysis, using complexing agents to attract and sequester these antigens. The company also holds provisional patents for multiple methods targeting COVID-19, emphasizing its distinct approach compared to conventional treatments. As a debt-free entity, Halberd is positioned to explore revolutionary medical techniques, although it faces potential regulatory scrutiny.
- Holds exclusive rights to multiple provisional patents for COVID-19 treatment.
- Debt-free status enhances financial stability and investor confidence.
- Innovative treatment method differentiates from conventional therapies, potentially positioning the company for significant market impact.
- Uncertainty regarding the long-term impact of COVID-19 on operations and finances.
- Regulatory scrutiny over claims related to COVID-19 initiatives may pose risks.
JACKSON CENTER, PA / ACCESSWIRE / August 18, 2020 / Halberd Corp. (OTC PINK:HALB) Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions.
Q: There are various extracorporeal medical procedures being researched or used and in various states of trial and approval. How do these differ from your patented process?
A: All extracorporeal processes have one thing in common - they all consist of removing something from the blood, or cerebral spinal fluid, while the bodily fluid is outside the patient. The difference is in how the offending substances - target disease antigens - are removed before the bodily fluid is returned to the body. Some methods use conventional mechanical filtration, others use chemical attraction, or other means to attract and trap the target antigens and remove them. Our patents, and pending patents, have unique features to the technology that are distinguishable from other extracorporeal processes which we believe gives us a technological edge and precludes others from pursuing a similar path.
Regardless of which extracorporeal process is employed, they all differ from conventional medical treatments in that conventional treatments involve adding something to the patient - drugs or chemicals administered through an IV, intramuscular injection, orally, trans-nasally or through inhalation. Extracorporeal treatments remove things from the patient - the disease antigens. This is the revolutionary aspect of our intended treatment.
Q: How does the extracorporeal process work?
A: Overall, the process is very similar to standard kidney dialysis. Blood is removed from the patient, and is pumped through a cartridge containing and retaining complexing molecules designed to attract the particular targeted disease antigen. After passing through the cartridge, the blood is returned to the patient, while the target antigens stay in the antigen cartridge. The process includes monitoring the concentrations of the target antigens in the incoming, pre-filtered blood, and also the cleansed blood returning to the patient as a key indicator of effectiveness of the "filtration" process.
Q: What are complexing agents?
A: Complexing agents are simply molecules that demonstrate a strong affinity for the target antigens. When these antigens are exposed to its corresponding designed complexing agent, they are attracted to, and sequestered by it, thereby enabling them to be removed from the blood. These complexing agents are permanently affixed to the interior surfaces of the cartridge for removal and disposal at the completion of the extracorporeal treatment. Since the capture and removal process is one of a molecular bond, it is a bit different than a normal mechanical filter which traps and removes particles based on their physical size. The attraction and capture of the antigens can be thought of like a magnet and iron filings.
Q: Can you elaborate a bit on these complexing agents? Are they broad in scope, like a magnet attracting all different grades of iron, or specific, targeting a single, specific antigen?
A: That depends on what you are looking to eliminate from the blood, or cerebral spinal fluid (CSF). We've only discussed here the application of the process to the blood, but it is equally applicable to CSF for diseases associated with spinal fluid.
There are a couple of ways of attacking a disease: you can remove the disease antigen directly, or remove one or more of the elements the disease needs to survive. So you can remove the antigen itself, or you can starve it to death. But this is not an either/or proposition. You can do both simultaneously. It just depends on the design intent is of the complexing agent(s) used in the treatment cartridge - single or multiple targets.
Our recent provisional patent application, Method for Treating and Curing Covid-19 Infection, addresses targeting the entire Covid-19 molecule - single target, while the provisional patent application, Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients, uniquely seeks a simultaneous removal of multiple targets related to elements which support the cytokine storm present in later-stage Covid-19 cases.
In this way, we believe we can selectively remove various disease causing agents from the blood or CSF depending on the design of the complexing agents - or "magnets" to use that analogy - used in the cartridge, without putting any drugs or chemicals into the patient. This greatly reduces or eliminated the chances of adverse reactions to the treatment. The process removes the toxic elements from the blood without disturbing the rest of the body.
This is distinctly different than a vaccine which often has the capacity of causing harm and in some cases more harm than good. And many people reject vaccination. Often our treatment may be the only alternative for people.
Q: You mentioned in earlier press releases about an extracorporeal process that uses a laser to eliminate the disease antigens. How does that work?
A: It works much the same way as described above, but instead of a complexing agent that attracts and holds it to the interior surfaces of a cartridge, it "lights up" the target antigen using a fluorescent chemical. Instead of a cartridge, a laser targeting area is created to enable the antigen-fluorescent conjugate pair to pass through the laser's focal area. At that stage they are detected by the nano laser targeting system and eliminated with a burst of controlled energy from the nano laser. The nano laser is highly focused, and controlled, to eliminate any collateral damage to surrounding cells.
Q: Where do you get the complexing agents for use in your treatment process?
A: That is where our partnership with one or more research universities comes in. Halberd's scientists have identified antigen targets we believe need to be removed from the blood in order to rid the body of Covid-19. We will be directing one or more of our university partner(s) to develop agents that will selectively attract and capture the target antigens. These complexing agents will then need to be permanently attached to the inner surfaces of the filtration cartridge and then tested for safety and efficacy. These are the first steps in a development sequence that we believe could lead to a technique to remove any number of viruses from the human body and could ultimately revolutionize medicine.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
About Halberd Corporation.
HalberdCorporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Title | Application No. | Filing Date | Priority | Status |
Method for Treating and Curing Covid-19 Infection | US 62/989981 | 03/16/2020 | n/a | Provisional application Pending |
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US 63/007207 | 04/08/2020 | n/a | Provisional application Pending |
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US 63/013104 | 4/21/2020 | n/a | Provisional application Pending |
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/602148/Halberd-Corporation-CEO-Answers-Shareholders-Questions-Regarding-Covid-19-Treatment
FAQ
What is Halberd Corporation's approach to COVID-19 treatment?
What provisional patents does HALB hold?
How does Halberd's extracorporeal process differ from conventional treatments?
What is the financial status of Halberd Corporation?
What challenges does Halberd face concerning its COVID-19 treatment claims?
